Overview

Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy

Status:
Recruiting

Trial end date:
2026-04-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to determine the safety and efficacy of cabozantinib in the management of unresectable or metastatic hepatocellular carcinoma (HCC) with underlying Child-Pugh class B cirrhosis.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Michigan Rogel Cancer Center

Collaborator:

Exelixis